Previous Close | 3.64 |
1-Year Change | 96.76% |
6-Months Change | 22.15% |
3-Months Change | -3.7% |
Moving Avg (50d) | 3.9792 |
Moving Avg (200d) | 3.3595 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 0.69B |
Beta (3-Years) | 0.95 |
Revenue Growth (ttm) | -69.69% |
Net Profit Margin (ttm) | -1137.64% |
Return On Assets (ttm) | -54.61% |
EPS (ttm) | -0.43 |
PE Ratio (ttm) | -8.47 |
Dividend Yield | % |
Asset Description: | Arbutus Biopharma Corporation |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-10-15 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
3.44 | 3.334 | 3.264 | 3.159 | 2.983 | 2.808 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |